• Megumi Shimoyama, Hazel H Szeto, Peter W Schiller, Yugo Tagaito, Hideyuki Tokairin, Chong moon Eun, and Naohito Shimoyama.
• Department of Anesthesiology, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan. shimoyama-teii@umin.ac.jp
• Pharmacology. 2009 Jan 1; 83 (1): 33-7.

AimsH-Dmt-D-Arg-Phe-Lys-NH(2) ([Dmt(1)]DALDA), a highly selective micro-opioid peptide, is potently analgesic after systemic and intrathecal administration but is less potent given intracerebroventricularly. This study was performed to further characterize the analgesic effects of [Dmt(1)]DALDA.MethodsWe compared the effects of [Dmt(1)]DALDA and morphine after systemic administration in two different acute pain tests, the tail flick test and the paw withdrawal test, and examined how antagonizing the spinal opioid actions would affect their analgesic effects.Results[Dmt(1)]DALDA was markedly more potent in the tail flick test than in the hot plate test, while the potencies of morphine were similar in the two tests. Intrathecal naloxone completely blocked the effect of systemic [Dmt(1)]DALDA in the tail flick test, while it only partially blocked the effect of morphine. At higher doses that produced analgesia in the hot plate test, the effect of [Dmt(1)]DALDA in this test was only partially blocked by naloxone.ConclusionSystemic [Dmt(1)]DALDA has a unique analgesic property clearly different from that of morphine and it has a propensity to produce spinal analgesia.

30 keywords...

hide…